HIV molecular immunology database

 

Search Antibody Database

Found 1 matching record:

Displaying record number 478

Download this epitope record as JSON.

MAb ID SP.SF2:104
HXB2 Location gp160(308-317)
DNA(7146..7175)
gp160 Epitope Map
Author Location gp120( SF2)
Epitope SIYIGPGRAF Epitope Alignment
SIYIGPGRAF epitope logo
Ab Type gp120 V3 // V3 glycan (V3g)
Neutralizing L
Species (Isotype) (IgG2aκ)
Patient  
Immunogen HIV-1 infection
Keywords  

Notes

Showing 2 of 2 notes.

References

Showing 2 of 2 references.

Arendrup1993 M. Arendrup, A. Sonnerborg, B. Svennerholm, L. Akerblom, C. Nielsen, H. Clausen, S. Olofsson, J. O. Nielsen, and J. E. S. Hensen. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J. Gen. Virol., 74:855-863, 1993. PubMed ID: 7684062. Show all entries for this paper.

Arendrup1995 M. Arendrup, L. Akerblom, P. M. Heegaard, J. O. Nielsen, and J. E. Hansen. The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies. Arch. Virol., 140:655-670, 1995. The anti-V3 Ab titre in patient serum was generally low against autologous virus isolated later than the serum sample, in contrast to a higher titre against peptides corresponding to virus isolated earlier than the serum sample. The authors conclude that the V3 domain is subject to immunoselection in vivo, and that V3 on early field virus is less accessible to NAbs than the V3 loop on laboratory strains. PubMed ID: 7794110. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health